1. Home
  2. ZVRA vs CBLL Comparison

ZVRA vs CBLL Comparison

Compare ZVRA & CBLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Zevra Therapeutics Inc.

ZVRA

Zevra Therapeutics Inc.

HOLD

Current Price

$8.65

Market Cap

499.9M

Sector

Health Care

ML Signal

HOLD

Logo CeriBell Inc.

CBLL

CeriBell Inc.

HOLD

Current Price

$19.20

Market Cap

428.8M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
ZVRA
CBLL
Founded
2006
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
499.9M
428.8M
IPO Year
2015
2024

Fundamental Metrics

Financial Performance
Metric
ZVRA
CBLL
Price
$8.65
$19.20
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
7
5
Target Price
$21.71
$24.20
AVG Volume (30 Days)
1.4M
449.8K
Earning Date
11-05-2025
11-04-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.54
N/A
Revenue
$84,388,000.00
$82,813,000.00
Revenue This Year
$336.43
$37.43
Revenue Next Year
$54.26
$27.87
P/E Ratio
$16.12
N/A
Revenue Growth
244.60
37.93
52 Week Low
$6.19
$10.01
52 Week High
$13.16
$32.75

Technical Indicators

Market Signals
Indicator
ZVRA
CBLL
Relative Strength Index (RSI) 43.13 81.41
Support Level $8.12 $16.27
Resistance Level $8.75 $17.39
Average True Range (ATR) 0.51 0.87
MACD -0.01 0.45
Stochastic Oscillator 33.21 98.08

Price Performance

Historical Comparison
ZVRA
CBLL

About ZVRA Zevra Therapeutics Inc.

Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.

About CBLL CeriBell Inc.

CeriBell Inc is a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. The Company has developed the Ceribell System, a novel, point-of-care electroencephalography (EEG) platform specifically designed to address the unmet needs of patients in the acute care setting. By combining proprietary, portable and rapidly deployable hardware with sophisticated artificial intelligence (AI) powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions.

Share on Social Networks: